Other headlines for [GENZ]

• GENZ 11/24/2008 11:32am
  Genzyme Corp Files supplemental NDA with FDA for use of Clolar to treat patients with acute myeloid leukemia- The company has requested priority review of its application and, if granted, Clolar could be approved more...
  
• GENZ 11/17/2008 04:05pm
  Genzyme Corp Forms Collaboration with International Center for Genetic Engineering and Biotechnology to Advance Treatments for Neglected Diseases- The collaboration between Genzyme and ICGEB will initially focus more...
  
• GENZ 11/17/2008 09:03am
  Genzyme Corp Reconfirms FY 2009 EPS guidance of $4.70 v $4.74e- Announces that the FDA plans an Accelerated Approval for Myozyme produced at the 2000 L bioreactor scale for the treatment of late Onset Pompe more...
  
• OSIR 11/4/2008 07:45am
  Osiris Therapeutics Inc Partners with Genyme to develop and commercialize adult stem cell products, sees $130M upfront payment- Entered into strategic alliance for the development and commercialization of Prochymal and more...
  
• GENZ 10/22/2008 06:52pm
  Genzyme Corp Price Target lowered to $88 from $93 at Merrill, maintains buy rating
  

Healthcare sector headlines

• CUR Today 08:02am
  Neuralstem Inc Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials- The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with Dr. more...
  
• SVA Today 08:01am
  Sinovac Biotech Announces share buyback of up to $2M (5.5% of market cap)
  
• PRX Today 08:01am
  Par Pharmaceutical Companies Inc. Announces successful completion of Bioequivalence Studies for Ondansetron Thin Film- The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea and more...
  
• CSKI Today 08:01am
  China Sky One Medical, Inc. Names Yu-Bo Hao new CFO- He replaces Yu-kun Zhang, who had served as interim CFO since June, 2008. - Mr. Hao has been employed at China Sky One in various capacities since June, 2008. - From more...
  
• THRX Today 08:01am
  Theravance Inc Announces positive Phase 2b results for LABA, '444 in the Horizon Asthma Development Programme with GSK- The study, which was designed to evaluate the efficacy of five doses of '444 administered more...